Freenome, Inc. (FRNM)
Snapshot
- 1 week
- +8.7%+9.1% vs SPY
- 1 month
- -18.7%-17.6% vs SPY
- Market cap
- $104.2M
- Short % float
- 47.8%
- Days to cover
- 3.3
- Short change
- +100.4%
- Price target
- $18.25+42.9% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Freenome, Inc. (FRNM). Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administratio…
- Aaron ElliottCEO & DirectorUSD 1.2M
- Cheng-Ho LinChief Scientific OfficerUSD 742K
- Robert GuigleyChief Commercial Officer
- Thomas F. FitzpatrickChief Legal Officer
- Julie Tran MSHRChief People Officer
- Sally HowardSenior Vice President of Regulatory & Quality
Snapshot
Price & returns1 month -18.7%
- 1 week
- +8.7%+9.1% vs SPY
- 1 month
- -18.7%-17.6% vs SPY
Valuationmarket cap $104.2M
- Market cap
- $104.2M
Short interest & optionsshort 47.8% of float
- Short % float
- 47.8%
- Days to cover
- 3.3
- Short change
- +100.4%
Street & earningsTarget $18.25 (+42.9% upside)
- Price target
- $18.25+42.9% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Freenome, Inc. (FRNM). Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administratio…
- Aaron ElliottCEO & DirectorUSD 1.2M
- Cheng-Ho LinChief Scientific OfficerUSD 742K
- Robert GuigleyChief Commercial Officer
- Thomas F. FitzpatrickChief Legal Officer
Company news
Congress trades
STOCK Act filings · … on file